BEDMINSTER, N.J., Oct. 25 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:
NPSP) announced today that it will report its third quarter financial results
and Nycomed's decision whether to proceed with ex-U.S. development and
commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007.
NPS expects to receive notification from Nycomed at the end of this month
regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM)
(teduglutide) outside North America. The announcement will be followed by a
conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles,
president and CEO, and other members of the NPS executive team.
To participate in the conference call, dial (866) 770-7051 and use
passcode 53288322. International callers may dial (617) 213-8064, using the
same passcode. In addition, live audio of the conference call will be
simultaneously broadcast over the Internet and may be accessed on the
company's web site (http://www.npsp.com).
If you are unable to participate in the live call, a replay will be
available at (888) 286-8010, with passcode 16038876, until midnight EST,
November 15, 2007. International callers may access the replay by dialing
(617) 801-6888, using the same passcode. The webcast will also be available on
the NPS website for the same period of time.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The company has drug candidates in various
stages of clinical development. Additional information is available on the
company's website, http://www.npsp.com.
For further information:
For further information: Brandi Simpson of NPS Pharmaceuticals, Inc.,
+1-908-450-5616 Web Site: http://www.npsp.com